President's Cancer Panel Recommendations and Responsible Stakeholders

A broad set of stakeholders must contribute to efforts to align cancer drug prices with their value, ensure affordable access to cancer drugs for all patients, and promote future innovation in cancer drug development. This table identifies stakeholders (listed alphabetically) that could play important roles in implementing the Panel’s recommendations to achieve these goals. Stakeholder lists are not necessarily exhaustive. Further, inclusion in this table does not indicate endorsement of the Panel recommendations.

Recommendation	Responsible Stakeholders
1. Promote value-based pricing and use of cancer drugs.	Biopharmaceutical companies Center for Medicare & Medicaid Innovation Federal and state policy makers Healthcare providers Healthcare systems Institute for Clinical and Economic Review Medicare Payment Advisory Commission National Academies of Sciences, Engineering, and Medicine National Association of Insurance Commissioners Patients, families/caregivers, and patient advocacy organizations (e.g., Patient Power, NCCS, LIVESTRONG Foundation, FasterCures) Pharmaceutical supply chain organizations (e.g., pharmacy benefit managers, wholesalers, retailers) Professional associations (e.g., ASCO, AHIP) Public and private payers
2. Enable meaningful communication about treatment options, including cost information, to support patients’ decision making.	Center for Medicare & Medicaid Innovation Federal and state policy makers Healthcare providers Healthcare systems National Comprehensive Cancer Network Patients, families/caregivers, and patient advocacy organizations (e.g., Patient Power, NCCS, LIVESTRONG Foundation, FasterCures) Professional associations (e.g., ASCO, ONS) Public and private payers Research funding organizations (NIH/NCI, DoD, PCORI, nonprofit/advocacy organizations [e.g., ACS]) Researchers
3. Minimize the contributions of drug costs to financial toxicity for cancer patients and their families.	Cancer care teams Congress Healthcare systems Medicare Payment Advisory Commission Patients, families/caregivers, and patient advocacy organizations (e.g., Patient Power, NCCS, LIVESTRONG Foundation) President Public and private payers Research funding organizations (e.g., NIH/NCI, nonprofit/advocacy organizations [e.g., ACS]) Researchers Secretary of the U.S. Department of Health and Human Services
4. Stimulate and maintain competition in the generic and biosimilar cancer drug markets.	Biopharmaceutical companies Congress Federal Trade Commission U.S. Department of Health and Human Services U.S. Department of Justice U.S. Food and Drug Administration and FDA Commissioner
5. Ensure that FDA has appropriate resources to assess cancer drug safety and efficacy efficiently.	Congress President
6. Invest in biomedical research to create a strong foundation for developing innovative, high-value cancer drugs.	Academic institutions Biopharmaceutical companies Congress President Research advocacy organizations (e.g., AAAS, AAMC, Research!America, FasterCures) Research funding organizations (NIH/NCI, DoD, nonprofit/advocacy organizations, [e.g., ACS]) Researchers Venture capital companies

Note: AAAS = American Association for the Advancement of Science, AAMC = Association of American Medical Colleges, ACS = American Cancer Society, AHIP = America’s Health Insurance Plans, ASCO = American Society of Clinical Oncology, DoD = U.S. Department of Defense, FDA = U.S. Food and Drug Administration, NCCS = National Coalition for Cancer Survivorship, NCI = National Cancer Institute, NIH = National Institutes of Health, ONS = Oncology Nursing Society, PCORI = Patient-Centered Outcomes Research Institute

« Previous Next »